Document is current
Any future updates will be listed below
-
Authors
Korte, Eva W. H. https://orcid.org/0000-0001-9166-5654
van den Akker, Peter C. https://orcid.org/0000-0002-3734-753X
Kiritsi, Dimitra https://orcid.org/0000-0002-2331-8981
Kottner, Jan https://orcid.org/0000-0003-0750-3818
Pasmooij, Anna M. G. https://orcid.org/0000-0003-0641-3829
Prinsen, Cecilia A. C. https://orcid.org/0000-0002-0956-3788
Wally, Verena https://orcid.org/0000-0001-8705-3890
Welponer, Tobias https://orcid.org/0000-0003-3159-0720
Spuls, Phyllis I. https://orcid.org/0000-0002-6035-2863
Laimer, Martin https://orcid.org/0000-0002-6932-0374
Bolling, Maria C. https://orcid.org/0000-0003-2086-9363
,
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 10 August 2025
First Online: 9 October 2025
Declarations
:
: The central Ethics Review Board non-WMO studies of the University Medical Center Groningen (CTc UMCG) has approved the current study (METc 2024/475). The data protection officer at each participating center will be involved. Written informed consent will be obtained from patients participating in the qualitative studies. Informed consent for the participants in the Delphi survey is unnecessary; however, all participants will need to express their willingness to participate and their consent to use of their data.
: Not applicable.
: E. K., P. A., A. P., J. K., C. P., T. W., and M. L. declare that they have no competing interests. D. K. has served as a consultant for Amryt Pharma, Fibrx Inc., and RHEACELL GmbH and is co-founder of Crowd Pharma, a company focusing on repurposing losartan for EB. V. W. acts as consultant for and holds shares of Diaderm GmbH. P. S. receives departmental independent research grants for TREAT NL registry from Pharma since December 2019; is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, e.g., psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital; and is chief investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children. She participated in the development of one of the HOME core outcome instruments (Recap of atopic eczema (RECAP)) and in the development of the Outcome Measures for VAscular Malformations (OVAMA) questionnaire for vascular malformations. M. B. has served in the Advisory Boards of Amryt Pharma and Krystal Biotech Inc.
